Lipid profile of women using oral contraceptive pills

Pakistan Journal of Biological Sciences

Volumn 15, Issue 19, 2012, Pages 947-950

  Naz, F ^a   Jyoti, S ^a   Akhtar, N ^b   Afzal, M ^a   Siddique, Y H ^a  

^a ALIGARH MUSLIM UNIVERSITY   (India)

^b ALIGARH MUSLIM UNIVERSITY   (India)

Author keywords

Biochemical parameters; Healthy women; Oral contraceptives

Indexed keywords

EID: 84874896568     PISSN: 10288880     EISSN: 18125735     Source Type: Journal    
DOI: 10.3923/pjbs.2012.947.950     Document Type: Article

References (38)

1. Abdel-Barry, J.A., M.S. Flafl, L.M. Al-Namaa and N.A. Hassan, 2011. Lipoprotein changes in women taking low-dose combined oral contraceptive pills: A cross-sectional study in Basra, Iraq. East. Mediterr. Health J., 17: 684-688.
2. Anonymous, 1986. Oral-contraceptive use and the risk of breast cancer. N. Engl. J. Med., 315: 405-411.
3. Avins, A.L., R.J. Haber and S.B. Hulley, 1989. The status of hypertriglyceridemia as a risk factor for coronary heart disease. Clin. Lab. Med., 9: 153-168.
4. Brinton, L.A., D.R. Brogan, R.J. Coates, C.A. Swanson, N. Potischman and J.L. Stanford, 1998. Breast cancer risk among women under 55 years of age by joint effects of usage of oral contraceptives and hormone replacement therapy. Menopause, 5: 145-151.
5. Emokpae, M.A., P.O. Uadia and H.B. Osadolar, 2010. Effect of duration of use of hormonal contraceptive pills on total lipid and lipoproteins in Nigerian women. Int. J. Pharm. Bio. Sci., 1: 1-5.
6. Farmer, R.D. and R.A. Lawrenson, 1998. Oral contraceptives and venous thromboembolic disease: The findings from database studies in the United Kingdom and Germany. Am. J. Obstet Gynecol., 179: S78-86.
7. Garnero, P., E. Sornay-Rendu and P.D. Delmas, 1995. Decreased bone turnover in oral contraceptive users. Bone, 16: 499-503.
8. Godsland, I.F., D. Crook, R. Simpson, T. Proudler and C. Felton et al., 1990. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N. Engl. J. Med., 323: 1375-1381.
9. Hankinson, S.E., G.A. Colditz, J.E. Manson, W.C. Willett, D.J. Hunter, M.J. Stampfer and F.E. Speizer, 1997. A prospective study of oral contraceptive use and risk of breast cancer (Nurses Health Study, United States). Cancer Causes Control., 8: 65-72.
10. Kemmeren, J.M., A. Algra and D.E. Grobbee, 2001. Third generation oral contraceptives and risk of venous thrombosis: Meta-analysis. BMJ, 323: 131-134.
11. Marchbanks, P.A., J.A. McDonald, H.G. Wilson, S.G. Folger and M.G. Mandel et al., 2002. Oral contraceptives and the risk of breast cancer. N. Engl. J. Med., 346: 2025-2032.
12. Nawrot, T.S., E.D. Hond, R.H. Fagard, K. Hoppenbrouwers and J.A. Staessen, 2003. Blood pressure, serum total cholesterol and contraceptive pill use in 17-year-old girls. Eur. J. Cardiovasc. Prevention Rehab., 10: 438-442.
13. Naz, F., S. Jyoti, M. Afzal and Y.H. Siddique, 2012. Biochemical effects of oral contraceptive among users: A review. Int. J. Pharmacol., 8: 314-320.
14. Newman, W.P., W. Bao, W. Wattigney and G.S. Berenson, 1991. Autopsy studies in United States children and adolescents. Relationship of risk factors to atherosclerotic lesions. Ann. N. Y. Acad. Sci., 623: 16-25.
15. Obisesan, K.A., F.A. Adenaike, M.A. Okunlola and A.A. Adenaike, 2002. Effect of oral contraceptives on total serum proteins, albumin, globulin and cholesterol levels in Ibadan, Nigeria. West Afr. J. Med., 21: 197-199.
16. Rosing, J. and G. Tans, 1999. Effects of oral contraceptives on hemostasis and thrombosis. Am. J. Obstet Gynecol., 180: S375-382.
17. Schaefer, E.J., D.M. Faster, L.A. Zec, F.T. Lindgren, H.B. Brewer Jr. and R.I. Levy, 1983. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J. Clin. Endocrinol. Metab., 57: 262-267.
18. Siddique, Y.H. and M. Afzal, 2004. Evaluation of genotoxic potential of synthetic progestin chlormadinone acetate. Toxicol. Lett., 153: 221-225.
19. Siddique, Y.H. and M. Afzal, 2005. Genotoxic potential of cyproterone acetate: A possible role of reactive oxygen species. Toxicol. In vitro, 19: 63-68.
20. Siddique, Y.H. and M. Afzal, 2005. Protective role of allicin and L-ascorbic acid against the genotoxic damage induced by chlormadinone acetate in cultured human lymphocytes. Indian J. Exp. Biol., 43: 769-772.
21. Siddique, Y.H. and M. Afzal, 2008. A review on the genotoxic effects of some synthetic progestins. Int. J. Pharmacol., 4: 410-430.
22. Siddique, Y.H., G. Ara, T. Beg and M. Afzal, 2006. Effect of vitamin C on cyproterone acetate induced genotoxic damage in mice. Res. J. Biol. Sci., 1: 69-73.
23. Siddique, Y.H., T. Beg and M. Afzal, 2005. Genotoxic potential of ethinylestradiol in cultured mammalian cells. Chem. Biol. Interact., 151: 133-141.
24. Siddique, Y.H., T. Beg and M. Afzal, 2005. Antigenotoxic effects of ascorbic acid against megestrol acetate induced genotoxicity in mice. Hum. Exp. Toxicol., 24: 121-127.
25. Siddique, Y.H., T. Beg and M. Afzal, 2006. Protective role of nordihydroguaiaretic acid (NDGA) against norgestrel induced genotoxic damage. Toxicol. In Vitro, 20: 227-233.
26. Sitruk-Ware, R. and A. Nath, 2011. Metabolic effects of contraceptive steroids. Rev. Endocr. Metab. Disord., 12: 63-75.
27. Sitruk-Ware, R., 2006. New progestagens for contraceptive use. Hum. Reprod. Updatet, 12: 169-178.
28. Skouby, S.O., J. Endrikat, B. Dusterberg, W. Schmidt and C. Gerlinger et al., 2005. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrel. Contraception, 71: 111-117.
29. Stampfer, M.J., W.C. Willett, G.A. Colditz, F.E. Speizer and C.H. Hennekens, 1990. Past use of oral contraceptives and cardiovascular disease: A meta-analysis in the context of the nurses health study. Am. J. Obstet. Gynecol., 163: 285-291.
30. Thorvaldsen, P., K. Asplund, K. Kuulasmaa, A.M. Rajakangas and M. Schroll, 1995. Stroke incidence case fatality and mortality in the WHO MONICA project. World Health Organization monitoring trends and determinants in cardiovascular disease. Stroke, 26: 361-367.
31. Tzankova, V., V. Petrov and N. Danchev, 2010. Impact of oral contraceptives and smoking on arterial and deep venous thrombosis: A{cyrillic} retrospective case-control study. Biotechnol. Biotechnol. Eq., 24: 2026-2030.
32. Van Hylckama Vlieg, A., F.M. Helmerhorst, J.P. Vandenbrouck, C.J.M. Doggen and F.R. Rosendaal, 2009. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: Results of the MEGA case-control study. BMJ, Vol. 339 10.1136/bmj. b2921
33. Vessey, M.P., M. Lawless and D. Yeates, 1984. Oral contraceptives and stroke: Findings in a large prospective study. Br. Med. J., 289: 530-531.
34. WHO, 1996. Haemorrhagic stroke, overall stroke risk, and combined oral contraceptives: Results of an international, multicentre, case-control study. Lancet, 348: 505-510.
35. Weiss, G., 1999. Risk of venous thromboembolism with third-generation oral contraceptives: A review. Am. J. Obstet. Gynecol., 180: 295-301.
36. Westhoff, C.L., 1998. Oral contraceptives and thrombosis: An overview of study methods and recent results. Am. J. Obstet. Gynecol., 179: S38-S42.
37. Wynn, J.W., J.W. Doar and G.L. Mills, 1966. Some effects of oral contraceptives on serum-lipid and lipoprotein levels. Lancet, 2: 720-723.
38. Young, R.L. and A. DelConte, 1999. Effects of low-dose monophasic levonorgestrel with ethinyl estradiol preparation on serum lipid levels: A twenty-four month clinical trial. Am. J. Obstet. Gynecol., 181: 59-62.